Biotech Stocks Targeting High Value Indications

Hemespherx BioPharma HEB Stock News

The biotechnology space is a booming one, with a mix of technological and medical innovation leading to advanced treatments of incredible value. Not only are the biotechnology companies of today bringing improved quality and extended length of life to patients, they’re also bringing incredibly profitable opportunities to investors.  When looking into a potential biotechnology investment, … Read more

Regeneron Pharmaceuticals (REGN) Stock: Gaining Big On Earnings

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company reported its fourth quarter results, blowing away expectations and leading to excitement among investors. Today, we’ll talk about what we saw from earnings, what we’re seeing from the stock as a result, and … Read more

Regeneron Pharmaceuticals (REGN) Stock: Gaining On Strong Earnings

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is having an incredibly strong start in the pre-market hours this morning, and for good reason. The company reported earnings, blowing away analyst expectations and exciting investors. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (7:46), REGN is trading … Read more

Regeneron Pharmaceuticals (REGN) Stock: Gains On Breakthrough Therapy Designation

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Regeneron Pharmaceuticals is having a relatively strong start to the day today, and for good reason. The company received Fast Track Designation with regard to one of its lead candidates. As a result, investors got exciting, pushing the stock slightly. At the moment (8:45), REGN is trading at $379.57 per … Read more

Regeneron Pharmaceuticals (REGN) Stock: Here’s Why It’s Tanking

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Regeneron Pharmaceuticals is having an overwhelmingly hard day in the market today, and for good reason. Investors have seen news that the approval for a lead candidate may be delayed from the FDA. Below, we’ll talk about what we’re seeing from the stock, why, and what we can expect to … Read more

Regeneron Pharmaceuticals (REGN): Strong On High Volume & Earnings Expectations

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Regeneron Pharmaceuticals is having a strong day in the market today after announcing when their next earnings report will be released. This continues a bullish trend that we’ve seen on the stock since October 6th. Today, we’ll talk about when earnings are expected and what analyst expectations are, the volume … Read more

Analysts Weigh In on Regeneron Pharmaceuticals Inc (REGN) Following Earnings Report

By Cody Miecnikowski On Tuesday, August 4, before market open, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported its second-quarter 2015 financial results that beat both top and bottom line expectations. The biotech giant, which recently won approval for its cholesterol drug, Praluent, said its profit doubled in its second quarter as sales of Eylea, its eye-disease treatment, surged. Specifically, the company’s revenue jumped 50% year-over-year to $998.6 … Read more

Today In Biotech: Lexicon Pharmaceuticals (LXRX), Synergy Pharmaceuticals (SGYP), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD)

Lexicon Pharmaceuticals Declines After Yesterday’s Gains Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) Lexicon Pharmaceuticals had an incredible day in the market yesterday after releasing top-line data from its phase 3 study of telotristat etiprate. The study looked into the efficacy and tolerability with regard to the medication as a treatment for cancer patients with carcinoid syndrome. … Read more

Regeneron Pharmaceuticals (REGN) Tops Q2 Earnings

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Regeneron Pharmaceuticals stock is having a great day in the market today after releasing its results from the second quarter. Today, we’ll take a look at REGN’s Q2 results, how investors reacted to the news, and what we can expect to see moving forward. So, let’s get right to it… … Read more